

9<sup>th</sup> April 2024

## DIRECT HEALTHCARE PROFESSIONAL COMMUNICATION

### **Wegovy® 0.5 mg, solution for injection in pre-filled pen (semaglutide): Interim supply of Swiss Stock to Mitigate Supply Disruption**

Dear Healthcare Professional,

#### **Summary:**

To ensure continuity in supply, Novo Nordisk has obtained approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to supply Swiss product Wegovy® 0.5 mg, solution for injection in pre-filled pen batch PP5K970, 18,137 packs, batch expiry 30/11/2026 which is expected to be on the UK market from May to June 2024.

Please note the following:

- This product is considered licensed in the UK
- The product from Switzerland has the same formulation as the UK product
- The product from Switzerland is manufactured according to the same manufacturing process and quality controls as the UK product
- There are language differences on the packaging and also in the product information leaflet (PIL) as shown in below images.
- Please ensure the UK approved [Summary of Product Characteristics](#) (SPC) and [Patient Information Leaflet](#) (PIL) are followed.
- The additional documents included in the inner bag are intended for the patient. Please ensure they receive them.
- The MHRA has approved this product under a batch specific variation to the marketing authorisation.

Please ensure all relevant staff are made aware of the content of this letter and that the information is communicated to patients.

Please advise patients to continue recording the weekday of their injection and the date of each weekly dose as shown on the UK packaging below



The diagram shows a section of the packaging with a circular icon at the top and a triangle pointing to it, with the text "Lift here" below. Below this is a box containing the text "Use wegovy® once a week". Underneath, there are two lines of text: "Write the weekday you choose to inject" followed by a large empty box, and "I injected my weekly dose on the below dates" followed by four small empty boxes.

#### Images of Swiss product

(Note that the labelling is the same; the only differences are the language)



A copy of the UK Patient Information Leaflet (PIL) will be included with each product pack.

### Call for reporting

Please continue to report suspected adverse drug reactions (ADRs) to the MHRA through the Yellow Card scheme.

Please report:

- all suspected ADRs that are serious or result in harm. Serious reactions are those that are fatal, life-threatening, disabling or incapacitating, those that cause a congenital abnormality or result in hospitalisation, and those that are considered medically significant for any other reason
- all suspected ADRs associated with new drugs and vaccines identified by the black triangle ▼

You can report via:

- the [Yellow Card website](#)
- the free Yellow Card app available from the Apple App Store or Google Play Store
- some clinical IT systems (EMIS/SystemOne/Vision/MiDatabank) for healthcare professionals

Alternatively, you can report a suspected side effect to the Yellow Card scheme by calling 0800 731 6789 for free, Monday to Friday between 9am and 5pm.

When reporting please provide as much information as possible, including information about medical history, any concomitant medication, timing onset, treatment dates, and product brand name.

### Company contact point

If you have any questions about this letter or require more information about the use of Wegovy®, please contact Novo Nordisk Customer Care Centre on 0800 023 2573 or email [CustomerCare@novonordisk.com](mailto:CustomerCare@novonordisk.com)

Yours faithfully,

Avideh Nazeri MD MBA *Avideh Nazeri*  
 Vice President  
 Clinical Development, Medical & Regulatory Affairs (CMR) UK